NorthRock Partners LLC Buys 27,914 Shares of Pfizer Inc. (NYSE:PFE)

NorthRock Partners LLC increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 111.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53,016 shares of the biopharmaceutical company's stock after purchasing an additional 27,914 shares during the quarter. NorthRock Partners LLC's holdings in Pfizer were worth $1,407,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the 4th quarter worth $27,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the fourth quarter valued at about $28,000. Finally, Noble Wealth Management PBC acquired a new stake in Pfizer in the fourth quarter valued at about $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 3.8%

Shares of PFE stock opened at $22.01 on Thursday. The stock has a 50-day moving average of $23.80 and a 200-day moving average of $25.44. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $125.13 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the business earned $0.82 EPS. The company's revenue was down 7.8% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.81%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.